Benign Neoplasm

3

Review clinical trials related to Benign Neoplasm. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Fluid Challenge and Plasma Volume, During Surgery

A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.

Participants needed: 60
Trial details
Phase: Phase 4Age: 18-85Biological sex: AllType: InterventionalSponsor: Joachim ZdolsekUpdated: Apr 30, 2026Locations: 1
Eligibility criteria

Written consent to participate in the study [+4]

Patients with known cardiac failure [+5]

Status: Recruiting

Intraoperative Tumor Margin Identification With ICG Dye Imaging

In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Apr 24, 2026Locations: 1
Eligibility criteria

All patients 18 years of age or older who present to Massachusetts General Hospi...

Pregnant or nursing patients [+2]

Status: Available

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

This expanded access protocol studies bone marrow transplantation using CD34-selected stem cells from related or unrelated donors in treating participants with cancer or other disorders. Stem cells collected from the donor will be processed using a new device called CliniMACS CD34 Reagent System which marks the blood cells collected from the donor with a special protein called "antibody" that tags only the donor stem cells, sorting out other cells of the blood and immune system. This is done to remove, at least partially, some of the T cells. T cells are the cells in the blood that work as scavengers of the immune system deciding what belongs and what does not. These cells can sometimes cause rejection of the donor graft or a condition called graft-versus host disease (GVHD), where the donor cells can attack the body of the recipient. A bone marrow transplantation using CD34-selected stem cells may reduce the risk of these unwanted side effects of transplant as much as possible.

Trial details
Age: Up to 70Biological sex: AllType: Expanded AccessSponsor: OHSU Knight Cancer InstituteUpdated: Jan 2, 2026Locations: 1
Eligibility criteria

Patients with malignant or nonmalignant diseases that can benefit from alternati... [+8]

Patients not meeting clearance criteria for bone marrow transplantation (BMT) ba... [+2]